Regenerative Research: Stem Cells, Exosomes and Platelet-Rich Plasma in Context
A short, plain summary of stem cell, exosome and platelet-rich plasma research, what regulators warn about, and how it differs from peptide products.
Content last updated . This page has not been medically reviewed.
What this page covers
"Regenerative" is a marketing word as well as a research field. This page is a short summary of three topics that often appear next to peptides in clinic advertising: stem cells, exosomes and platelet-rich plasma (PRP). It is deliberately brief. The full treatment of regenerative and molecular technologies belongs to Emerging Wellness Science, and the guide to what counts as emerging wellness science explains how we judge such claims. Peptides, cells and exosomes are different kinds of things: a peptide is a short chain of amino acids, while stem cells are living cells and exosomes are tiny packages released by cells.Evidence labels used here
We use plain labels: approved medicine, established, promising but limited, mixed, insufficient evidence, preclinical (cells or animals only), no good evidence of benefit, evidence of harm and marketing claim. They apply to one specific use at a time, never to a whole field.Stem cells
Evidence differs enormously by condition. In a 2023 systematic review of mesenchymal stem cell therapy for traumatic spinal cord injury, 22 studies (21 clinical trials and one case series) were included. They consistently showed improvements in neurological grading, and the cell therapy looked safe over the short and medium term. [3] The authors still caution against general recommendations because the evidence is limited and long-term safety is unclear. [3] Evidence label for that use: promising but limited. It says nothing about stem cell products offered for other conditions, and it describes studied cell therapies, not products sold at clinics.Exosomes
Exosomes are small packages that cells release to communicate with each other. A 2022 review of clinical trials found them being tested as biomarkers, cell-free treatments, drug carriers and cancer vaccines, and said the mechanisms behind the observed effects remain far from fully understood. [4] It also notes that clinical use must meet manufacturing standards and that major questions remain. [4] Separately, in December 2019 FDA warned the public of serious adverse events in patients in Nebraska who were treated with unapproved products marketed as containing exosomes. [5] Evidence label for exosome products sold to consumers: insufficient evidence, with a regulator warning of harm in specific cases.Platelet-rich plasma
PRP is made from a person's own blood. The RESTORE placebo-controlled trial in knee osteoarthritis randomized 288 adults aged 50 or older to three PRP injections or saline. [6] After 12 months, pain change was -2.1 points with PRP and -1.8 with saline, and cartilage volume change was also similar. [6] The authors concluded the findings do not support PRP for managing knee osteoarthritis. [6] That is one trial of one product in one condition, so it is not a verdict on every use of PRP. Evidence label for this use: no good evidence of benefit from this trial.How peptides differ
Peptide products marketed for healing are a separate topic with separate evidence. See peptides and wound healing, tendon and ligament injury claims and the claim check on "peptides heal any injury". A result for cells, exosomes or PRP does not transfer to a peptide, and the reverse is also true.Frequently asked questions
Are stem cell clinics offering approved treatments?
For most conditions, not in the United States. FDA says the only approved stem cell products are blood-forming cells from cord blood, for blood-system disorders. [1]
Are exosome products approved?
FDA's regenerative medicine page lists exosomes among unapproved products marketed for a wide range of conditions. [1] FDA also issued a public safety notification about serious adverse events after exosome-labeled products. [5]
Does PRP work for knee arthritis?
In one large placebo-controlled trial it did not outperform saline at 12 months. [6] Other uses and products would need their own evidence.
Is a ClinicalTrials.gov listing a sign a product is approved?
No. FDA says inclusion in that database does not mean a product is legally marketed. [1]
Is this the same as peptide therapy?
No. Peptides are short amino acid chains; cells, exosomes and PRP are different materials with different evidence. See the peptide research landscape.
More details: evidence, limits and cautions
The details behind this page: cautions, limits of the evidence and where sources disagree. Open any note to read it.
What the U.S. regulator says
The U.S. Food and Drug Administration (FDA) says that, on its regenerative medicine page (content current as of April 2024), the only stem cell products it has approved are blood-forming stem cells from umbilical cord blood, approved for disorders of the blood-forming system and not for other uses. [1] The same page warns that unapproved products marketed for a wide range of conditions include stem cells, fat-derived cells, cord blood, amniotic fluid, Wharton's jelly, ortho-biologics and exosomes. [1] FDA reports receiving accounts of blindness, tumor formation and infections linked to such products. [1] It also notes that listing on ClinicalTrials.gov, or a firm registering with FDA, does not mean a product is legally marketed. [1] This is a statement about U.S. rules; other countries have their own regulators. FDA also keeps a separate list of licensed cellular and gene therapy products, such as idecabtagene vicleucel. [2]
Safety note
Cell, exosome and PRP treatments are medical procedures with real risks. Anyone considering one should ask whether it is part of a regulated clinical trial and talk with a licensed clinician. See talking with a health professional.
References
- U.S. Food and Drug Administration. Important Patient and Consumer Information About Regenerative Medicine Therapies (content current as of 04/08/2024). Read 2026-10-22.
- U.S. Food and Drug Administration. Approved Cellular and Gene Therapy Products. Read 2026-10-22.
- Montoto-Meijide R et al. Mesenchymal Stem Cell Therapy in Traumatic Spinal Cord Injury: A Systematic Review. Int J Mol Sci 2023. PubMed. Read 2026-10-22.
- Rezaie J et al. A review on exosomes application in clinical trials: perspective, questions, and challenges. Cell Commun Signal 2022. PubMed. Read 2026-10-22.
- U.S. Food and Drug Administration. Public Safety Notification on Exosome Products (December 6, 2019). Read 2026-10-22.
- Bennell KL et al. Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial. JAMA 2021. PubMed. Read 2026-10-22.
Education, not medical advice. This page is for general information. It does not diagnose or treat any condition and is not a substitute for care from a qualified health professional. Natural does not automatically mean safe. Ask a clinician or pharmacist before changing your care, especially if you take medication, are pregnant or breastfeeding, or have a health condition.